Los Angeles Capital Management’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
Other funds holding NAGE
SW
TCM
Los Angeles Capital Management's NAGE Position: Q2 2026 in Review
Los Angeles Capital Management reduced its Niagen Bioscience (NAGE) stake by 91% in Q2 2026, selling an estimated $1.78M and leaving 42,191 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #1274.
Los Angeles Capital Management first reported a position in NAGE in Q2 2021 and has held it in 8 quarters since. The position peaked at $2.12M in Q1 2026. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Los Angeles Capital Management held 42,191 shares of Niagen Bioscience worth $135K as of Q2 2026.
- Los Angeles Capital Management sold 439,251 Niagen Bioscience shares in Q2 2026, an estimated $1.78M.
- Niagen Bioscience made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1274 holding.
- Los Angeles Capital Management first reported a position in Niagen Bioscience in Q2 2021 and has held it in 8 quarters since.
- Los Angeles Capital Management's Niagen Bioscience position peaked at $2.12M in Q1 2026.
- 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.